CNM-Au8 Improved Brain’s Energetic Profile in Parkinson’s Patients

CNM-Au8 Improved Brain’s Energetic Profile in Parkinson’s Patients

307128

CNM-Au8 Improved Brain’s Energetic Profile in Parkinson’s Patients

CNM-Au8, an experimental oral treatment by Clene Nanomedicine, was safe and led to improvements in the brain’s energetic profile — thought to protect against cell death — in adults with Parkinson’s disease, according to data from the Phase 2 clinical trial REPAIR-PD. “In addition to achieving its primary [goal], the [REPAIR-PD] study reinforced our lead candidate CNM-Au8’s central nervous system target engagement, as well as its ability to significantly rebalance brain [energetic] metabolites, both of…

You must be logged in to read/download the full post.